Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
national blog main
san francisco blog main
8
×
boston blog main
boston top stories
national top stories
raleigh-durham blog main
san francisco top stories
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
deals
fda
medical device
alnylam pharmaceuticals
avexis
bristol-myers squibb
cancer
cancer drugs
cancer immunotherapy
celgene
colorectal cancer
What
disease
8
×
drug
medicines
roundup
bio
cancer
companies
established
fight
known
liver
lung
nash
new
news
race
therapy
according
adds
advanced
akcea
alliance
alnylam’s
alzheimer's
approval
approved
areas
bad
better
bff
biosciences
biotech
bio’s
brain
brii
building
california
cancer’s
case
cases
Language
unset
Current search:
biotech
×
disease
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed